Meet Geoffrey Parker, the Chief Financial Officer and Executive Vice President at Allogene Therapeutics. With a strong background in finance, he brings valuable experience to the company. Geoffrey graduated from Dartmouth College with a double major in Economics and Engineering...

Meet Geoffrey Parker, the Chief Financial Officer and Executive Vice President at Allogene Therapeutics. With a strong background in finance, he brings valuable experience to the company. Geoffrey graduated from Dartmouth College with a double major in Economics and Engineering Sciences and earned his MBA from Stanford. Before joining Allogene in 2023, he held key positions at Tricida, Inc. and Anacor Pharmaceuticals, the latter of which was acquired by Pfizer for around $5.2 billion. His previous role at Goldman Sachs involved leading the West Coast Healthcare Investment Banking group. In his new role at Allogene, Geoffrey is highly invested and has a significant compensation package, indicating strong trust in his leadership potential. His hands-on experience in the pharmaceutical industry and a solid educational foundation position him as an exciting figure within Allogene, especially as the company focuses on innovative treatments in the field of cell therapy.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Allogene Therapeutics CEOs

A

Geoffrey Parker

CEO of Allogene Therapeutics

Education

B.A. in Economics and Engineering Sciences from Dartmouth College; MBA from Stanford Graduate School of Business

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

January 1, 1965 - 60 years ago

CEO of Allogene Therapeutics for

1 year 5 months (Oct 2023 - Present)

Previous Experience

Chief Operating Officer, Chief Financial Officer and Executive Vice President of Tricida, Inc.

Rivals

Competitors/colleagues of Geoffrey Parker

Holdings

See how much did Geoffrey Parker make over time.

As of his appointment at Allogene Therapeutics, Geoffrey Parker holds impressive options and restricted stock units that highlight his commitment to the company. In 2023 alone, he received stock options to purchase approximately 950,000 shares, aligning his interests with those...

As of his appointment at Allogene Therapeutics, Geoffrey Parker holds impressive options and restricted stock units that highlight his commitment to the company. In 2023 alone, he received stock options to purchase approximately 950,000 shares, aligning his interests with those of shareholders. Moreover, he has 400,000 shares in restricted stock units, vesting over four years, which suggests that he has skin in the game. His total 2023 compensation amounted to about $1.47 million, which includes a combination of salary, bonus, and vested stock. With such a significant amount linked to Allogene's stock performance, it shows that Geoffrey is well positioned to share in the company's future successes, especially as it works towards regulatory approvals for its therapies. His holdings reflect not just a personal wealth interest but also a shared destiny with the company.

Loading...

Total Stock Sold

$7.28K

ALLO

$7.28K

4,361 ALLO shares

What if they kept their stock?

If Geoffrey Parker didn't sell their stock, today they would have:
Extra ALLO4,361 shares worth $90.93K.
This is 1,148.5% and $83.64K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Geoffrey Parker.

ALLO

$7.54K

ALLO at $1.73/share

Feb 3, 2025

Sale

ALLO

173,913 shares

ALLO

Jan 24, 2025

Received

ALLO

$1.00M

ALLO at $2.90/share

May 16, 2024

Received

ALLO

$683.05

ALLO at $3.60/share

Jan 30, 2024

Purchase

ALLO

29,400 shares

ALLO

Jan 25, 2024

Received

ALLO

790,000 shares

ALLO

Oct 16, 2023

Received

PRGO

$330.64K

PRGO at $33.06/share

Jun 13, 2023

Purchase

PRGO

$190.27K

PRGO at $38.05/share

Mar 6, 2023

Purchase

PRGO

$184.27K

PRGO at $36.85/share

Dec 16, 2021

Purchase

PRGO

$103.22K

PRGO at $41.29/share

Mar 17, 2021

Purchase

Compensation History

See how much did Geoffrey Parker make over time.

For the year 2023, Geoffrey Parker's total compensation reached approximately $1.47 million. This includes a base salary of $724,000 and a bonus of $270,595, which he earned based on meeting corporate performance goals. Additionally, he received the value of vested stock worth about $1.43 million, stemming from restricted stock units that vest over time. His compensation structure emphasizes performance and aligns with long-term shareholder interests. With a significant portion tied to equity awards, it's clear that Geoffrey's incentives are linked to the company's growth, enhancing the chances that he will drive results that benefit both him and the shareholders.

Year

2023

Total Compensation

$2.42M

Salary

$724.00K

Board Justification

The compensation philosophy is designed to align executive compensation with performance and long-term shareholder value, with a significant portion of compensation tied to equity awards and performance metrics.

Bonus

$270.60K

Board Justification

Annual performance-based cash incentive earned for the year 2023, based on corporate goals achievement.

Other

$0.00

Board Justification

No additional compensation reported for 2023.

Restricted Stock

$1.43M(444.11K RSU)

Board Justification

Restricted Stock Units (RSUs) that vest 25% annually over four years, with 444,107 shares vested in 2023.

Performance Metrics

Performance metrics include achieving corporate goals related to clinical development and operational performance.

Other Allogene Therapeutics CEOs

Here are other CEOs of Allogene Therapeutics

David Chang, M.D., Ph.D.

Founder and Ex-CEO of Allogene Therapeutics

December 2018 - October 2023